The initiation of coverage by Cantor Fitzgerald with an Overweight rating and a price target of $25 indicates a positive outlook for Ambrx Biopharma. This news is likely to have a positive short-term impact on the stock price as it suggests that the analyst believes the stock is undervalued and has potential for growth.